دورية أكاديمية
أعرض في EDS

Anti-KIF20B autoantibodies are associated with cranial neuropathy in systemic lupus erythematosus.

التفاصيل البيبلوغرافية
العنوان: Anti-KIF20B autoantibodies are associated with cranial neuropathy in systemic lupus erythematosus.
المؤلفون: Krustev E; Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada., Hanly JG; Division of Rheumatology, Department of Medicine and Department of Pathology, Queen Elizabeth II Health Sciences Centre and Dalhousie University, Halifax, Nova Scotia, Canada., Chin R; Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada., Buhler KA; Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada., Urowitz MB; Lupus Program, Centre for Prognosis Studies in The Rheumatic Disease and Krembil Research Institute, Toronto Western Hospital and University of Toronto, Toronto, Ontario, Canada., Gordon C; Rheumatology Research Group, Institute of Inflammation and Ageing, College of Medical and Dental Sciences, University of Birmingham, Birmingham, UK., Bae SC; Department of Rheumatology, Hanyang University Hospital for Rheumatic Diseases, Hanyang University Institute for Rheumatology and Hanyang Institute of Bioscience and Biotechnology, Seoul, Republic of Korea., Romero-Diaz J; Immunology and Rheumatology, Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Ciudad de Mexico, Mexico., Sánchez-Guerrero J; Mount Sinai Hospital and University Health Network, Toronto, Ontario, Canada., Bernatsky S; Divisions of Rheumatology and Clinical Epidemiology, McGill University Health Centre, Montreal, Quebec, Canada., Wallace DJ; Rheumatology, Cedars-Sinai Medical Center, Los Angeles, California, USA.; David Geffen School of Medicine, University of California Los Angeles, Los Angeles, California, USA., Isenberg D; Centre for Rheumatology, Department of Medicine, University College London, London, UK., Rahman A; Centre for Rheumatology, Department of Medicine, University College London, London, UK., Merrill JT; Department of Clinical Pharmacology, Oklahoma Medical Research Foundation, Oklahoma City, Oklahoma, USA., Fortin PR; Division of Rheumatology, CHU de Québec, Universite Laval, Quebec City, Quebec, Canada., Gladman DD; Lupus Program, Centre for Prognosis Studies in The Rheumatic Disease and Krembil Research Institute, Toronto Western Hospital and University of Toronto, Toronto, Ontario, Canada., Bruce IN; Centre for Musculoskeletal Research, Faculty of Biology, Medicine and Health, The University of Manchester and The Kellgren Centre for Rheumatology, Manchester University Hospitals NHS Foundation Trust, Manchester Academic Health Science Centre, Manchester, UK., Petri MA; Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA., Ginzler EM; Medicine, SUNY Downstate Medical Center, New York City, New York, USA., Dooley MA; Thurston Arthritis Research Center, The University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA., Ramsey-Goldman R; Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA., Manzi S; Allegheny Health Network, Pittsburgh, Pennsylvania, USA., Jönsen A; Department of Rheumatology, Lund University Department of Clinical Sciences Lund, Lund, Sweden., Alarcón GS; Department of Medicine, The University of Alabama at Birmingham Heersink School of Medicine, Birmingham, Alabama, USA., van Vollenhoven RF; Department of Rheumatology and Clinical Immunology, University of Amsterdam, Amsterdam, Noord-Holland, The Netherlands., Aranow C; Center for Autoimmune and Musculoskeletal Disease, Northwell Health Feinstein Institutes for Medical Research, Manhasset, New York, USA., Mackay M; Center for Autoimmune and Musculoskeletal Disease, Northwell Health Feinstein Institutes for Medical Research, Manhasset, New York, USA., Ruiz-Irastorza G; Autoimmune Diseases Research Unit, Department of Internal Medicine, BioCruces Health Research Institute, Hospital Universitario Cruces, University of the Basque Country, Barakaldo, Spain., Lim S; Division of Rheumatology, Emory University School of Medicine, Atlanta, Georgia, USA., Inanc M; Division of Rheumatology, Department of Internal Medicine, Istanbul Medical Faculty, Istanbul University, Fatih, Turkey., Kalunian KC; University of California San Diego School of Medicine, La Jolla, California, USA., Jacobsen S; Department of Rheumatology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark., Peschken CA; University of Manitoba, Winnipeg, Manitoba, Canada., Kamen DL; Medical University of South Carolina, Charleston, South Carolina, USA., Askenase A; Columbia University Medical Center, New York City, New York, USA., Buyon J; Rheumatology, NYU Langone Health, New York City, New York, USA., Fritzler MJ; Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada., Clarke AE; Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada., Choi MY; Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada may.choi@ucalgary.ca.; McCaig Institute for Bone and Joint Health, Calgary, Alberta, Canada.
المصدر: Lupus science & medicine [Lupus Sci Med] 2024 Apr 09; Vol. 11 (1). Date of Electronic Publication: 2024 Apr 09.
نوع المنشور: Journal Article
اللغة: English
بيانات الدورية: Publisher: BMJ Country of Publication: England NLM ID: 101633705 Publication Model: Electronic Cited Medium: Print ISSN: 2053-8790 (Print) Linking ISSN: 20538790 NLM ISO Abbreviation: Lupus Sci Med Subsets: MEDLINE
أسماء مطبوعة: Original Publication: London : BMJ, [2014]-
مواضيع طبية MeSH: Autoantibodies* , Kinesins* , Lupus Erythematosus, Systemic*/complications , Lupus Erythematosus, Systemic*/diagnosis, Female ; Humans ; Male ; Biomarkers
مستخلص: Background: Cranial neuropathies (CN) are a rare neuropsychiatric SLE (NPSLE) manifestation. Previous studies reported that antibodies to the kinesin family member 20B (KIF20B) (anti-KIF20B) protein were associated with idiopathic ataxia and CN. We assessed anti-KIF20B as a potential biomarker for NPSLE in an international SLE inception cohort.
Methods: Individuals fulfilling the revised 1997 American College of Rheumatology (ACR) SLE classification criteria were enrolled from 31 centres from 1999 to 2011 and followed annually in the Systemic Lupus Erythematosus International Collaborating Clinics inception cohort. Anti-KIF20B testing was performed on baseline (within 15 months of diagnosis or first annual visit) samples using an addressable laser bead immunoassay. Logistic regression (penalised maximum likelihood and adjusting for confounding variables) examined the association between anti-KIF20B and NPSLE manifestations (1999 ACR case definitions), including CN, occurring over the first 5 years of follow-up.
Results: Of the 1827 enrolled cohort members, baseline serum and 5 years of follow-up data were available on 795 patients who were included in this study: 29.8% were anti-KIF20B-positive, 88.7% female, and 52.1% White. The frequency of anti-KIF20B positivity differed only for those with CN (n=10) versus without CN (n=785) (70.0% vs 29.3%; OR 5.2, 95% CI 1.4, 18.5). Compared with patients without CN, patients with CN were more likely to fulfil the ACR haematological (90.0% vs 66.1%; difference 23.9%, 95% CI 5.0%, 42.8%) and ANA (100% vs 95.7%; difference 4.3%, 95% CI 2.9%, 5.8%) criteria. In the multivariate analysis adjusting for age at baseline, female, White race and ethnicity, and ACR haematological and ANA criteria, anti-KIF20B positivity remained associated with CN (OR 5.2, 95% CI 1.4, 19.1).
Conclusion: Anti-KIF20B is a potential biomarker for SLE-related CN. Further studies are needed to examine how autoantibodies against KIF20B, which is variably expressed in a variety of neurological cells, contribute to disease pathogenesis.
Competing Interests: Competing interests: MYC has received consulting fees from AstraZeneca, GlaxoSmithKline, Werfen, Mallinckrodt Pharmaceuticals, Celltrion, Organon, and MitogenDx (less than $10 000). AEC has received consulting fees from AstraZeneca, Bristol Myers Squibb, GlaxoSmithKline, Roche and Otsuka (less than $10 000 each) and a research grant from GlaxoSmithKline. CG has received consulting fees, speaking fees and/or honoraria from AstraZeneca, AbbVie, Amgen, UCB, GlaxoSmithKline, Merck Serono and BMS (less than $10 000 each) and grants from UCB. Grants from UCB were given not to CG but to Sandwell and West Birmingham Hospitals NHS Trust. DDG received consulting fees, speaking fees and/or honoraria from GlaxoSmithKline (less than $10 000). INB has received consulting fees, speaking fees and/or honoraria from Eli Lilly, UCB, Roche, Merck Serono and MedImmune (less than $10 000 each), and grants from UCB, Genzyme, Sanofi and GlaxoSmithKline. EMG has paid consultation with investment analysts Guidepoint Global Gerson Lehrman Group. KCK has received grants from UCB, Human Genome Sciences/GlaxoSmithKline, Takeda, Ablynx, Bristol Myers Squibb, Pfizer and Kyowa Hakko Kirin, and has received consulting fees from Exagen Diagnostics, Genentech, Eli Lilly, Bristol Myers Squibb and Anthera (less than $10 000 each). MJF is Director of Mitogen Diagnostics Corporation (Calgary, Alberta, Canada) and a consultant to Werfen International (Barcelona, Spain), Grifols (Barcelona, Spain), Janssen Pharmaceuticals of Johnson & Johnson and Alexion Canada (less than $10 000 each).
(© Author(s) (or their employer(s)) 2024. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.)
References: Biomed Res Int. 2014;2014:524940. (PMID: 24864250)
Front Immunol. 2015 Aug 20;6:412. (PMID: 26347739)
Lupus. 2011 Nov;20(13):1426-32. (PMID: 22095889)
PLoS One. 2015 Mar 17;10(3):e0119911. (PMID: 25781014)
J Rheumatol. 2005 Jul;32(7):1267-72. (PMID: 15996063)
Arthritis Rheum. 1994 Mar;37(3):307-15. (PMID: 8129786)
Mol Biol Cell. 1996 Sep;7(9):1455-69. (PMID: 8885239)
Arthritis Rheum. 2006 Aug;54(8):2505-14. (PMID: 16868971)
Arthritis Rheumatol. 2020 Jan;72(1):67-77. (PMID: 31390162)
Rheum Dis Clin North Am. 2010 Feb;36(1):187-201, x-xi. (PMID: 20202599)
Acta Neurol Scand. 1989 Feb;79(2):114-8. (PMID: 2496575)
Arthritis Rheumatol. 2019 Jan;71(1):33-42. (PMID: 29927108)
J Rheumatol. 2001 Apr;28(4):766-71. (PMID: 11327248)
J Dermatol. 2023 Aug;50(8):990-998. (PMID: 37102216)
Ann Rheum Dis. 2020 Mar;79(3):356-362. (PMID: 31915121)
Ann Rheum Dis. 2011 Oct;70(10):1726-32. (PMID: 21893582)
Arthritis Rheumatol. 2018 Feb;70(2):277-286. (PMID: 29073350)
Ann Rheum Dis. 2022 Aug;81(8):1143-1150. (PMID: 35338033)
J Biol Chem. 2003 Jul 25;278(30):27844-52. (PMID: 12740395)
Ann Rheum Dis. 2010 Dec;69(12):2074-82. (PMID: 20724309)
Arthritis Rheum. 1999 Apr;42(4):599-608. (PMID: 10211873)
N Engl J Med. 2021 Jan 14;384(2):192-193. (PMID: 33497562)
J Investig Med. 2000 Jan;48(1):28-39. (PMID: 10695267)
Eur J Neurol. 2005 May;12(5):392-8. (PMID: 15804272)
Autoimmun Rev. 2020 Mar;19(3):102463. (PMID: 31927088)
Arthritis Rheum. 2001 Oct;45(5):419-23. (PMID: 11642640)
J Rheumatol. 2003 May;30(5):985-92. (PMID: 12734893)
J Clin Rheumatol. 2012 Sep;18(6):290-3. (PMID: 22955477)
Proc Natl Acad Sci U S A. 2020 Apr 28;117(17):9584-9593. (PMID: 32273386)
Arthritis Rheum. 1997 Sep;40(9):1725. (PMID: 9324032)
J Autoimmun. 2022 Oct;132:102892. (PMID: 36030137)
Development. 2013 Dec;140(23):4672-82. (PMID: 24173802)
Psychother Psychosom. 2012;81(5):276-85. (PMID: 22832425)
Neurology. 2003 Jan 14;60(1):127-9. (PMID: 12525735)
Monoclon Antib Immunodiagn Immunother. 2019 Aug;38(4):162-170. (PMID: 31260385)
معلومات مُعتمدة: R01 AR046588 United States AR NIAMS NIH HHS; M01 RR000046 United States RR NCRR NIH HHS; UL1 TR000150 United States TR NCATS NIH HHS; K24 AR002213 United States AR NIAMS NIH HHS; UL1 RR025741 United States RR NCRR NIH HHS; P30 AR072579 United States AR NIAMS NIH HHS; R01 AR043727 United States AR NIAMS NIH HHS; United Kingdom WT_ Wellcome Trust; R01 AR069572 United States AR NIAMS NIH HHS; P60 AR064464 United States AR NIAMS NIH HHS; P60 AR048098 United States AR NIAMS NIH HHS
فهرسة مساهمة: Keywords: Antibodies; Autoantibodies; Autoimmune Diseases; Systemic Lupus Erythematosus
المشرفين على المادة: 0 (Autoantibodies)
0 (Biomarkers)
EC 3.6.1.- (KIF20B protein, human)
EC 3.6.4.4 (Kinesins)
تواريخ الأحداث: Date Created: 20240410 Date Completed: 20240412 Latest Revision: 20240601
رمز التحديث: 20240601
مُعرف محوري في PubMed: PMC11015279
DOI: 10.1136/lupus-2023-001139
PMID: 38599670
قاعدة البيانات: MEDLINE
الوصف
تدمد:2053-8790
DOI:10.1136/lupus-2023-001139